Cartesian Therapeutics (RNAC) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 50.5% versus a loss of 15.2%. Over five years, SLGL leads with a -28.4% price change compared with -92.9% for RNAC. Cartesian Therapeutics is the larger company by market cap ($187.3 million vs $180.6 million), about 1.0 times the size, while Sol-Gel Technologies is growing revenue faster (+68.0% vs -92.8%).
Sol-Gel Technologies converts more of its revenue into profit, with a net margin of -31.6% versus -4658.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNAC | SLGL |
|---|---|---|
| Share price | $6.14 | $55.17 |
| Market cap | $187.29M | $180.63M |
| 1-day change | +4.24% | +2.02% |
| YTD return | -14.84% | +30.92% |
| 1-year return | -15.19% | +50.53% |
| 5-year return | -92.94% | -28.44% |
| EPS (TTM) | $-4.78 | $-5.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $19.39M |
| Revenue growth (YoY) | -92.81% | +68.04% |
| Net income (latest FY) | $-130.30M | $-6.13M |
| Operating margin | -5127.10% | -38.88% |
| Net margin | -4658.63% | -31.60% |
| 52-week high | $11.00 | $97.97 |
| 52-week low | $5.60 | $34.47 |
| Distance from 52-week high | -44.18% | -43.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +448.37% | +181.86% |
| Average volume | 139.65K | 47.38K |
| Shares outstanding | 30.50M | 3.27M |
| Employees | 75 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed RNAC by 65.7 percentage points over the past year.
- Sol-Gel Technologies is more profitable, keeping -31.6 cents of every revenue dollar as net income versus -4658.6 cents for Cartesian Therapeutics.
- Sol-Gel Technologies grew revenue faster in its latest fiscal year (+68.04% vs -92.81%).
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
RNAC vs SLGL FAQ
Which is bigger, Cartesian Therapeutics or Sol-Gel Technologies?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $187.29M compared with $180.63M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, RNAC or SLGL?
SLGL returned +50.53% over the past 12 months, compared with -15.19% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Cartesian Therapeutics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.